HK inno.N Corporation (195940.KQ) Stock
HK inno.N Corporation

Company profile
HK inno.N reported revenue of 1.06 trillion KRW for fiscal year 2025, up 18.5% from fiscal year 2024, and net income of 75.70 billion KRW. That is a net profit margin of 7.1% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 258.68 billion KRW, up 4.6% from a year before. In Q1 2026 it reported net income of 25.94 billion KRW, against net income of 17.43 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 828.91 billion KRW in fiscal year 2023 to 1.06 trillion KRW in fiscal year 2025, 13.3% a year on average. HK inno.N reports about 1,694 full-time employees.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About HK inno.N Corporation
HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. The company has joint research and development agreement with Nextgen Bioscience for NXC680, a candidate compound for treatment of Idiopathic Pulmonary Fibrosis. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.
Largest shareholders
- Kolmar Korea Co., Ltd.43.01%
- HK inno.N Corp. ESOA4.09%
- National Pension Service of Korea4.07%
- Value Partners Ltd.0.52%
- Amova Asset Management Asia Ltd.0.11%
Share of the company, as of September 25, 2026
Leadership
- Dal-Won Kwak — CEO, President & Director, 65
- WooSeong Kim — CFO & Director, 47
- Geun-Seok Song — Executive Director, 58
- Seong-bin Cho — Affiliate Executives
- Hwi-mun Kang — Affiliate Executive
How much revenue does HK inno.N make?
HK inno.N reported 1.06 trillion KRW in revenue for fiscal year 2025, up 18.5% from 897.14 billion KRW in fiscal year 2024. In Q1 2026 revenue was 258.68 billion KRW.
What companies are similar to HK inno.N?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include OliX Pharmaceuticals, Inc (226950.KQ), GC Biopharma Corp. (006280.KS), Daewoong Pharmaceutical Co., Ltd (069620.KS), Chong Kun Dang Pharmaceutical Corp. (185750.KS).
How has HK inno.N's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 769.79 billion KRW; FY2022, 846.52 billion KRW; FY2023, 828.91 billion KRW; FY2024, 897.14 billion KRW; FY2025, 1.06 trillion KRW.
Company Information
Data as of .
How to cite: DataPorium, “HK inno.N Corporation (195940.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/195940.KQ